Is there a role for neoadjuvant chemotherapy in upper-tract urothelial carcinoma?
Since the benefit of neoadjuvant chemotherapy is well-defined in muscle-invasive bladder cancer, is it reasonable to consider this in upper-tract tumors as well? Are there particular subgroups of patients who may be most appropriate?
1 Answer
Mednet MemberInvited Expert
Medical Oncology · University of Washington School of Medicine
Answered on
Very common scenario with significant variability in clinical practice. There is no standard high-level evidence as compared to muscle-invasive bladder urothelial cancer, in which neoadjuvant cisplatin-based chemotherapy is the standard of care for cisplatin-eligible patients. The literature lacks d...
Join for free or sign in to see the full answer